From: Physical activity and telomere length in early stage breast cancer survivors
 |  | Number | % |
---|---|---|---|
 |  | 392 | 100 |
Demographic characteristics | Age, years (mean, 61.97; SD, 10.36) | Â | Â |
  <55 | 91 | 23.2 | |
 |   55 to 65 | 170 | 43.4 |
 |   >65 | 131 | 33.4 |
 | BMI (mean, 27.21; SD, 5.85) |  |  |
 |   <25 | 163 | 41.6 |
 |   25 to 30 | 123 | 31.4 |
 |   >30 | 106 | 27.0 |
 | Smoking status |  |  |
 |   Never | 207 | 52.9 |
 |   Current | 13 | 3.3 |
 |   Previous | 171 | 43.7 |
 | Race/ethnicity |  |  |
 |   White | 322 | 82.1 |
 |   Non-white* | 70 | 17.9 |
 | Educational level |  |  |
 |   High school or less | 85 | 21.7 |
 |   College | 167 | 42.6 |
 |   Graduate or higher | 139 | 35.5 |
 | Marital status |  |  |
 |   Married/partnered | 244 | 62.2 |
 |   Single | 136 | 34.7 |
 | Physical activity |  |  |
 |   None | 66 | 16.8 |
 |   Moderate to vigorous | 326 | 83.2 |
Clinical characteristics | Stage | Â | Â |
  0 and I | 154 | 39.3 | |
 |   II | 192 | 49.0 |
 |   III | 46 | 11.7 |
 | Previous chemotherapy |  |  |
 |   No chemotherapy | 153 | 39.0 |
 |   Chemotherapy | 239 | 61.0 |
 | Current aromatase inhibitors |  |  |
 |   None | 41 | 10.5 |
 |   Letrozole | 67 | 17.1 |
 |   Anastrozole | 240 | 61.2 |
 |   Exemestane | 44 | 11.2 |
 | Cormorbid conditions |  |  |
 |   None | 62 | 15.8 |
 |   One | 118 | 30.1 |
 |   Two or more | 212 | 54.1 |
Symptom profile | HADS anxiety | Â | Â |
  Normal | 282 | 71.9 | |
 |   Symptomatic | 101 | 25.8 |
 | HADS depression |  |  |
 |   Normal | 344 | 87.8 |
 |   Symptomatic | 34 | 8.7 |